The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...

A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...

Ionis Pharmaceuticals IONS announced that it is floating a secondary issue of 11.5 million shares of its common stock to the ...

Bronchoscopic lung volume reduction (BLVR) was associated with sustained improvements in adults with severe emphysema over a 5-year period, based on data from 190 individuals. The LIBERATE study, a ...

The FDA allowed a generic drugmaker to leave out critical safety instructions when it approved a rival version of heart failure drug Entresto, Novartis Pharmaceuticals Corp., told a federal court. The ...

Judge Andrews of the District of Delaware recently denied Novartis’s request for a preliminary injunction against MSN Pharmaceuticals. Novartis Pharm. Corp. v. MSN Pharm. Inc., Civil Action No ...